Catalyst

Slingshot members are tracking this event:

Mylan (MYL) Senate Hearing Regarding Pricing of EpiPen on November 30th

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MYL

100%

Additional Information

Additional Relevant Details Mylan will not attend Senate hearing on EpiPen pricing 
http://www.reuters.c...
Additional Relevant Details Senate committee wants key players there, EpiPen hearing postponed
  • The Senate Judiciary Committee has postponed its hearing on EpiPen pricing as it "considers other avenues to ensure government and company witnesses participate."
  • The hearing was scheduled for November 30 but Mylan, representatives of the Justice Department and the Centers for Medicare & Medicaid Services (CMS) stated that they would not be able to attend due to "pending matters and investigations."
  • At issue is whether Mylan underpaid government healthcare plans by classifying EpiPen as generic in the Medicaid Drug Rebate Program.
http://seekingalpha....
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Senate, Epipen, Pricing